Drug Overview: Vraylar

Drug Overview: Vraylar

  • April 2018 •
  • 38 pages •
  • Report ID: 5391505 •
  • Format: PDF
Drug Overview 
Vraylar (cariprazine; Gedeon Richter/Allergan/Mitsubishi Tanabe) is a novel atypical antipsychotic with partial agonistic activity at D2 and D3 receptors, and selectivity for the D3 receptor. Vraylar is also a partial agonist at 5-HT1A receptors and an antagonist at 5-HT2A receptors. Most atypical antipsychotics have full antagonistic activity at D2 and 5-HT2A receptors, giving cariprazine a unique pharmacology among drugs in the class. 

Vraylar was initially developed as a drug for schizophrenia and bipolar disorder, and is now being investigated for the adjunctive treatment of major depressive disorder (MDD) as a line extension. Allergan has so far completed a single Phase III trial in MDD, which yielded negative data. Vraylar was first approved by the US Food and Drug Administration in September 2015.